ARTICLE | Clinical News
VB-201: Phase II data
February 23, 2015 8:00 AM UTC
VBL discontinued development of VB-201 to treat psoriasis after top-line data from a double-blind, European Phase II trial in 194 patients showed that 80 and 160 mg daily oral VB-201 for 24 weeks each...